Kerollos Nashat Wanis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kerollos Nashat Wanis has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Constance T. Albarracin
The University of Texas MD Anderson Cancer Center 2 Department of Anatomical Pathology Houston, Texas
9 shared publications - Isabelle Bedrosian
Department of Breast Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
9 shared publications Leora Sarvet
9 shared publications- Melissa Rangel
The University of Texas MD Anderson Cancer Center 1 Department of Breast Surgical Oncology Houston, Texas
9 shared publications - Nina Tamirisa
Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
9 shared publications - Puneet Singh
The University of Texas MD Anderson Cancer Center 1 Department of Breast Surgical Oncology Houston, Texas
9 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S2 shows Kaplan-Meier cumulative incidence of invasive cancer curves, with patients categorized according to whether they had undergone excision at 6 months or not.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S2 shows Kaplan-Meier cumulative incidence of invasive cancer curves, with patients categorized according to whether they had undergone excision at 6 months or not.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S3 shows the cumulative incidence of invasive cancer or DCIS curves under each treatment strategy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S3 shows the cumulative incidence of invasive cancer or DCIS curves under each treatment strategy.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S1 shows the baseline characteristics for all individuals eligible for the study.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S1 shows the baseline characteristics for all individuals eligible for the study.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S2 shows the cumulative incidence of invasive cancer or DCIS by year under each treatment strategy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S2 shows the cumulative incidence of invasive cancer or DCIS by year under each treatment strategy.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S4 shows points estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that used parametric standardization rather than inverse probability weighting.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S4 shows points estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that used parametric standardization rather than inverse probability weighting.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S3 shows point estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that varied the inverse probability weight truncation threshold.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Table S3 shows point estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that varied the inverse probability weight truncation threshold.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance:Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.See related Spotlight, p. 555
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance:Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.See related Spotlight, p. 555
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S1 is a flow diagram depicting the application of eligibility criteria used to derive the final analytic cohort.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
Supplementary Figure S1 is a flow diagram depicting the application of eligibility criteria used to derive the final analytic cohort.
- Open Access
- 21 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear. This target trial emulation, analyzing US commercial claims (2013–2023), evaluated these safety outcomes under gabapentin–opioids initiation vs. opioids only during the first postoperative month following breast cancer surgery, with sustained 1‐year follow‐up. Women with nonmetastatic breast cancer were eligible on surgery dates if they had no prior outcomes, nor gabapentinoids or opioid prescriptions. Outcomes included time‐to‐first respiratory complications, major adverse cardiovascular events (MACE), arrhythmia, and high‐dose opioid utilization (≥ 50 or ≥ 90 morphine ‐milligram equivalent [MME]). We estimated 1‐year outcome risks and 95% CIs under gabapentin–opioids and opioids‐only strategies using weighted pooled logistic regressions with bootstrapping, including stabilized inverse probability weighting to adjust for baseline and time‐varying confounders. Of 86,290 eligible individuals, 1709 initiated gabapentin and opioids, and 39,372 initiated opioids only. Risks of respiratory complications (RR 1.24, 95% CI: 0.26–3.02), MACE (RR 0.95, 95% CI: 0.31–1.85), and arrhythmia (RR 0.65, 95% CI: 0.24–1.33) were comparable under gabapentin–opioids and opioids‐only. Risk of receiving opioid dosage ≥ 50 MME (RR 1.23, 95% CI: 0.85–1.72) and ≥ 90 MME (RR 1.09, 95% CI: 0.43–2.23) were comparable. This study challenged the limited evidence regarding safety concerns of adding gabapentin for pain management, finding that gabapentin–opioids initiation carried comparable respiratory and cardiovascular risks to opioids only following breast cancer surgery. However, we did not find evidence that adjunctive gabapentin reduces subsequent high‐dose opioid utilization.
- 21 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessInitiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear. This target trial emulation, analyzing US commercial claims (2013–2023), evaluated these safety outcomes under gabapentin–opioids initiation vs. opioids only during the first postoperative month following breast cancer surgery, with sustained 1‐year follow‐up. Women with nonmetastatic breast cancer were eligible on surgery dates if they had no prior outcomes, nor gabapentinoids or opioid prescriptions. Outcomes included time‐to‐first respiratory complications, major adverse cardiovascular events (MACE), arrhythmia, and high‐dose opioid utilization (≥ 50 or ≥ 90 morphine ‐milligram equivalent [MME]). We estimated 1‐year outcome risks and 95% CIs under gabapentin–opioids and opioids‐only strategies using weighted pooled logistic regressions with bootstrapping, including stabilized inverse probability weighting to adjust for baseline and time‐varying confounders. Of 86,290 eligible individuals, 1709 initiated gabapentin and opioids, and 39,372 initiated opioids only. Risks of respiratory complications (RR 1.24, 95% CI: 0.26–3.02), MACE (RR 0.95, 95% CI: 0.31–1.85), and arrhythmia (RR 0.65, 95% CI: 0.24–1.33) were comparable under gabapentin–opioids and opioids‐only. Risk of receiving opioid dosage ≥ 50 MME (RR 1.23, 95% CI: 0.85–1.72) and ≥ 90 MME (RR 1.09, 95% CI: 0.43–2.23) were comparable. This study challenged the limited evidence regarding safety concerns of adding gabapentin for pain management, finding that gabapentin–opioids initiation carried comparable respiratory and cardiovascular risks to opioids only following breast cancer surgery. However, we did not find evidence that adjunctive gabapentin reduces subsequent high‐dose opioid utilization.
- 19 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (10) , OF1-OF10
Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance: Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.
- 19 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (10) , OF1-OF10
Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia
The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance: Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.